Insights into the role of IL-32 in cancer
- 1 August 2018
- journal article
- review article
- Published by Elsevier in Seminars in Immunology
- Vol. 38 (C) , 24-32
Abstract
No abstract availableKeywords
Funding Information
- the Netherlands Cancer Foundation (KWF) (#10559, 2017)
This publication has 74 references indexed in Scilit:
- Vessel co‐option in primary human tumors and metastases: an obstacle to effective anti‐angiogenic treatment?Cancer Medicine, 2013
- Antitumor activity of IL-32β through the activation of lymphocytes, and the inactivation of NF-κB and STAT3 signalsCell Death & Disease, 2013
- Therapeutic effectiveness of intratumorally delivered dendritic cells engineered to express the pro-inflammatory cytokine, interleukin (IL)-32Cancer Gene Therapy, 2011
- IL-32γ inhibits cancer cell growth through inactivation of NF-κB and STAT3 signalsOncogene, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factorsNature Reviews Cancer, 2010
- IL-32–dependent effects of IL-1β on endothelial cell functionsProceedings of the National Academy of Sciences, 2009
- Cancer-related inflammationNature, 2008
- Interleukin-32 induces the differentiation of monocytes into macrophage-like cellsProceedings of the National Academy of Sciences, 2008
- Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK functionProceedings of the National Academy of Sciences, 2008